By integrating gene‐level and pathway‐centric analyses, this study implements a rational and systematic approach to identify compounds with potential to disrupt MYC's transcriptional regulation activity without necessarily changing MYC's expression, which provides new insights on utilizing existing anticancer drugs to target MYC in MYC‐driven cancers. The gene discussed is MYC; the disease is cancer.